On October 7, PHARMARON fell 3.83% in regular trading, trading at 31.68 HKD, with turnover of 3.43 million HKD. The decline came as JPMorgan reduced its long position in PHARMARON H-shares by 3.94 million shares on October 1 due to release of share security interests, lowering its long position ratio from 14.99% to 13.9%.

Previously, JPMorgan also sold 1.15 million H-shares off-exchange at 31.35 HKD per share on September 30. The consecutive reduction moves suppressed market sentiment. On the same day, the broader CRO sector showed weakness, with WuXi Biologics down 2.85%, Genscript Biotech down 15.71%, and Insilico Medicine down 5.31%, reflecting cautious industry sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)